The Importance of Clinical Pharmacists in Improving Blood Glucose and Lipid Levels in Patients with Diabetes and Myocardial Infarction

References

• Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119
   PubMed Web of Science ®Google Scholar
• Milazzo V, Cosentino N, Genovese S, et al. Diabetes mellitus and acute myocardial infarction: impact on short and long-term mortality. Adv Exp Med Biol. 2021;1307:153–169. doi:10.1007/5584_2020_481
   PubMed Web of Science ®Google Scholar
• Gholap NN, Achana FA, Davies MJ, Ray KK, Gray L, Khunti K. Long-term mortality after acute myocardial infarction among individuals with and without diabetes: a systematic review and meta-analysis of studies in the post-reperfusion era. Diabetes Obes Metab. 2017;19:364–374. doi:10.1111/dom.12827
   PubMed Web of Science ®Google Scholar
• Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022;145:e722–e759. doi:10.1161/cir.0000000000001040
   PubMed Web of Science ®Google Scholar
• Del Valle KL, McDonnell ME. Chronic care management services for complex diabetes management: a practical overview. Curr Diab Rep. 2018;18:135. doi:10.1007/s11892-018-1118-x
   PubMed Web of Science ®Google Scholar
• Ishihara M, Kojima S, Sakamoto T, et al. Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. Am Heart J. 2005;150:814–820. doi:10.1016/j.ahj.2004.12.020
   PubMed Web of Science ®Google Scholar
• Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The diabetes mellitus–atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020;21:1835. doi:10.3390/ijms21051835
   PubMed Web of Science ®Google Scholar
• Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H. Diabetes dyslipidemia. Diabetes Therapy. 2016;7:203–219. doi:10.1007/s13300-016-0167-x
   PubMed Web of Science ®Google Scholar
• Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829–1839. doi:10.1016/s0140-6736(07)61778-4
   PubMed Web of Science ®Google Scholar
• Hegele R, Ginsberg H, Chapman M, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655–666. doi:10.1016/s2213-8587(13)70191-8
   PubMed Web of Science ®Google Scholar
• Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–1405. doi:10.1016/s0140-6736(14)61368-4
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. doi:10.1016/s0140-6736(10)61350-5
   PubMed Web of Science ®Google Scholar
• Martínez‐Mardones F, Fernandez‐Llimos F, Benrimoj SI, et al. Systematic review and meta‐analysis of medication reviews conducted by pharmacists on cardiovascular diseases risk factors in ambulatory care. J Am Heart Assoc. 2019;8:e013627. doi:10.1161/jaha.119.013627
   PubMed Web of Science ®Google Scholar
• Alshehri AA, Jalal Z, Cheema E, Haque MS, Jenkins D, Yahyouche A. Impact of the pharmacist‐led intervention on the control of medical cardiovascular risk factors for the primary prevention of cardiovascular disease in general practice: a systematic review and meta‐analysis of randomised controlled trials. Br J Clin Pharmacol. 2020;86:29–38. doi:10.1111/bcp.14164
   PubMed Web of Science ®Google Scholar
• Shi FH, Shen L, Yue J, et al. Intervention by clinical pharmacists can improve blood glucose fluctuation in patients with diabetes and acute myocardial infarction: a propensity score‐matched analysis. Pharmacol Res Perspect. 2021;9:e00725. doi:10.1002/prp2.725
   PubMed Web of Science ®Google Scholar
• Shi FH, Shen L, Pan MM, et al. The SUCCESSFUL RAPID ADJUSTMENT OF BLOOD GLUCOSE IN A PATIENT WITH ACUTE CORONARY SYNDROME, RENAL INSUFFICIENCY, AND DIABETES: A CASE REPORT OF MANAGEMENT COORDINATED BY CLINICAL PHARMACISTS AND CLINICIANS. Front Pharmacol. 2020;11:756. doi:10.3389/fphar.2020.00756
   PubMed Web of Science ®Google Scholar
• Chinese Endocrinologist C. M. D. A. iEgobgmfC. Expert consensus on blood glucose management for Chinese inpatients. Chin J Endocrinol Metab. 2017;33:1–10. doi:10.3760/cma.j.issn.1000-6699.2017.01.001
   Google Scholar
• Society CD, Endocrinology CSo. Expert consensus on glycated hemoglobin A1c targets and management algorithm for Chinese adults with type 2 diabetes mellitus. Chin J Diabetes Mellitus. 2020;12:1–12 doi:10.3760/cma.j.issn.1674-5809.2020.01.001.
   Google Scholar
• Society CD. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes Mellitus. 2021;13:315–409. doi:10.3760/cma.j.cn115791-20210221-00095
   Google Scholar
• Yihong S, Kang C, Xin C, et al. Expert consensus on the management of diabetic patients with cardiovascular diseases. Chin J Intern Med. 2021;60:421–437. doi:10.3760/cma.j.cn112138-20201208-00999
   PubMedGoogle Scholar
• Shi FH, Yue J, Jiang YH, et al. Sodium-glucose co-transporter 2 inhibitors use improves the satisfaction with anti-diabetic agent treatment: a questionnaire-based propensity score-matched study. Front Pharmacol. 2022;12:787704. doi:10.3389/fphar.2021.787704
   PubMed Web of Science ®Google Scholar
• Ertelt K, Brener SJ, Mehran R, Ben-Yehuda O, McAndrew T, Stone GW. Comparison of outcomes and prognosis of patients with versus without newly diagnosed diabetes mellitus after primary percutaneous coronary intervention for ST-elevation myocardial infarction (the HORIZONS-AMI Study). Am J Cardiol. 2017;119:1917–1923. doi:10.1016/j.amjcard.2017.03.016
   PubMedGoogle Scholar
• Webster K. Stress hyperglycemia and enhanced sensitivity to myocardial infarction. Curr Hypertens Rep. 2008;10:78–84. doi:10.1007/s11906-008-0015-0
   PubMed Web of Science ®Google Scholar
• Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J. 2004;25:1990–1997. doi:10.1016/j.ehj.2004.09.021
   PubMed Web of Science ®Google Scholar
• Planer D, Witzenbichler B, Guagliumi G, et al. Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the HORIZONS-AMI trial. Int J Cardiol. 2013;167:2572–2579. doi:10.1016/j.ijcard.2012.06.054
   PubMed Web of Science ®Google Scholar
• Thoegersen M, Josiassen J, Helgestad OKL, et al. The association of diabetes and admission blood glucose with 30-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2020;9:626–635. doi:10.1177/2048872620925265
   PubMed Web of Science ®Google Scholar
• Marenzi G, Cosentino N, Milazzo V, et al. Acute kidney injury in diabetic patients with acute myocardial infarction: role of acute and chronic glycemia. J Am Heart Assoc. 2018;7:e008122. doi:10.1161/jaha.117.008122
   PubMedGoogle Scholar
• Li Q. Expert consensus on the prevention and treatment of type 2 diabetes mellitus with dyslipidemia in China. Chin J Endocrinol Metab. 2017;33:925–934 doi:10.3760/cma.j.issn.1000-6699.2017.11.004.
   Google Scholar
• Sunil B, Ashraf AP. Dyslipidemia in pediatric type 2 diabetes mellitus. Curr Diab Rep. 2020;20:53. doi:10.1007/s11892-020-01336-6
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Stone NJ, Grundy SM. The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the management of blood cholesterol in diabetes. Diabetes Care. 2020;43:1673–1678. doi:10.2337/dci19-0036
   PubMed Web of Science ®Google Scholar
• Kearney P, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125. doi:10.1016/s0140-6736(08)60104-x
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano A, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188. doi:10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar